Active substances
Amylase + Lipase + Protease
- Health Canada 14
- UK MHRA 1
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| COTAZYM | 00263818 | 35000 UNIT; 10000 UNIT; 40000 UNIT | CAPSULE (IMMEDIATE-RELEASE) · ORAL | ORGANON CANADA INC. |
| COTAZYM ECS 20 | 00821373 | 25000 UNIT; 100000 UNIT; 100000 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | ORGANON CANADA INC. |
| COTAZYM ECS 8 | 00502790 | 10800 UNIT; 45000 UNIT; 42000 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | ORGANON CANADA INC. |
| CREON MINIMICROSPHERES 10 | 02200104 | 11200 UNIT; 730 UNIT; 10000 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | BGP PHARMA ULC |
| CREON MINIMICROSPHERES 25 | 01985205 | 25500 UNIT; 1600 UNIT; 25000 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | BGP PHARMA ULC |
| CREON MINIMICROSPHERES 35 | 02494639 | 35700 UNIT; 2240 UNIT; 35000 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | BGP PHARMA ULC |
| CREON MINIMICROSPHERES MICRO | 02445158 | 5000 UNIT / 100 MG; 320 UNIT / 100 MG; 5100 UNIT / 100 MG | GRANULES FOR SUSPENSION (DELAYED-RELEASE · ORAL | BGP PHARMA ULC |
| PANCREASE MT 10 | 00789437 | 25000 UNIT; 43750 UNIT; 10500 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | VIVUS LLC. |
| PANCREASE MT 16 | 00789429 | 70000 UNIT; 40000 UNIT; 16800 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | VIVUS LLC. |
| PANCREASE MT 2 | 02503433 | 10850 UNIT; 2600 UNIT; 6200 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | VIVUS LLC. |
| PANCREASE MT 20 | 02503441 | 61000 UNIT; 37000 UNIT; 21000 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | VIVUS LLC. |
| PANCREASE MT 4 | 00789445 | 10000 UNIT; 4200 UNIT; 17500 UNIT | CAPSULE (DELAYED-RELEASE) · ORAL | VIVUS LLC. |
| VIOKACE | 02230019 | 57100 UNIT; 56400 UNIT; 10440 UNIT | TABLET · ORAL | NESTLE ENTERPRISES S.A. |
| VIOKACE | 02241933 | 113400 UNIT; 20880 UNIT; 112500 UNIT | TABLET · ORAL | NESTLE ENTERPRISES S.A. |
UK MHRA United Kingdom — marketing authorisations
| Product | Authorisation | Holder | Legal status |
|---|---|---|---|
| PANCREX V CAPSULES 125MG | PL 41094/0005 | ESSENTIAL PHARMACEUTICALS LIMITED | P |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.